Bio-Communications Research Institute
High-dose intravenous vitamin C is safe for cancer patients, study says
Published in Health Risk Factor Week, April 11th, 2006
In this study, published in the Puerto Rico Health Sciences Journal, vol. 24 (4): 269-276, a phase I clinical trial with 24 terminal cancer patients receiving between 10-60 grams of sodium ascorbate daily for 8 weeks, adverse effects were reportedly minor. "The results presented in this manuscript should allay fears about the safety of 'mega-dose' vitamin C," said Dr. Joseph Casciari, coauthor of the manuscript.
This research comes on the heels of independent studies demonstrating efficacy of high-dose...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Risk Factor Week
More Articles from Health Risk Factor Week
- American College of Cardiology
Researchers find viable new sources for stem cell transplants to the heart - American Society for Aesthetic Plastic Surgery
Venous thromboembolic prophylaxis in plastic surgery stressed to reduce risk of blood clots - Callisto Pharmaceuticals, Inc.
First Berlin issues research update with buy rating on Callisto Pharmaceuticals - Emory University, Atlanta
Mother-adolescent HIV prevention program increases condom use and improves communication - ATS Medical, Inc.
ATS Medical reports first implant of Simulus annuloplasty ring - AUSL Rimini
CD4 count at end of HAART interruption influences duration of first interruption - More from this issue of Health Risk Factor Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
